Date post: | 18-Dec-2015 |
Category: |
Documents |
Upload: | prudence-maxwell |
View: | 217 times |
Download: | 1 times |
Global Presence of GlaxoSmithKline
•GSK GSK is one of the industry leaders, with an estimated seven per cent of the world's pharmaceutical market.
•GSK R&D GSK R&D has 24 sites in 7 countries and the budget is about £2.4bn/$4bn.
•Global Manufacturing and SupplyGlobal Manufacturing and Supply: GSK has 108 manufacturing sites in 41 countries
•GSK has over 100,000 employees worldwide
OutlineTo bear witness of the views of
various GSK senior executives on
the challenge of improving healthcare
who can help industry’s role and principles
Peter
Our mission“Our global quest is to
improve the quality of human life by enabling people to do more, feel better and live longer”
But: Many people in developing countries do not have access to basic health care services, including safe and effective medicines
Our commitment addresses three critical areas:
1. Investment in research and development to the developing world
2. Sustainable preferential pricing
3. Community activities that promote effective healthcare
Sustainable Preferential Pricing
Current scheme: all Least Developed Countries and all
countries in Sub-Saharan Africa Governments, international agencies,
NGOs, charities and international purchase funds; employers
all HIV, all anti-malarials pilot for anti-infectives, de-worming
agents and anti-diarrhoeals
Sustainability of preferential pricing
no prices below costs
no benchmarking of prices to developed world
no product diversion/parallel trade of preferential priced products
partnership
full IP Protection
Access to medicines
is a complex and multifaceted issue, rooted in poverty
– limited access to food and clean water
– shortage of hospitals and clinics to administer medicines
– poor distribution networks
– high levels of illiteracy
– low numbers of trained healthcare workers
– lack of political will: health as a priority
A rich R & D pipeline for the developing world: 20 active projects
hepatitis E vaccine, meningitis A and C combination vaccine, new diphtheria, tetanus, pertussis, hepatitis B vaccine, Malaria LAPDAP, for resistant infections, LAPDAP + artesunate (CDA), for acute, uncomplicated malaria; Malarone in the treatment of infants, children; Malarone in complicated, severe malaria; tafenoquine for the prevention of malaria; a tuberculosis vaccine (in collaboration with Corixa); tuberculosis chemotherapy (in partnership with the National Institutes of Health and St. Jude’s Children’s Research Hospital); Oxibendazole (for women of child-bearing age); sitamaquine for visceral leishmaniasis; a new combination product and a novel protease inhibitor for HIV/AIDS
Photos (taken out to reduce data)
What about Intellectual Property?
Patent protection stimulates and fundamentally underpins continued research and development
Focus on IP and the TRIPs agreement in the access debate is misleading and counter-productive:
95% of EDL medicines protected, 30% people no access
countries without IP have no better access: India only 15% of ARVs are patent protected TRIPS not implemented yet in many countries (50%) preferential priced products are available
TRIPS and Doha
TRIPS contains inbuilt flexibilities to safeguard public health, eg Compulsory licensing, parallel trade
no reopening necessary
any clarification in line with existing agreement